Cal-Maine Foods
CALM
62.70
-0.70
-1.10%
Cal-Maine Foods
US · CALM
#2479 by market cap
Listed 1970
62.70
-0.70
-1.10%
Live - 5344 symbols - heartbeat 259s ago
· 2026-10-08 08:17
Pre-market
63.06
+0.57%
After-hours
62.70
0.00%
- Market cap
- 2.93B
- P/E (TTM)i
- 50.16
- P/Bi
- 1.14
- EPSi
- 6.63
- Div yieldi
- 3.91%
- 52W posi
- 2%
Reader sentiment
Are you bullish or bearish on CALM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 6.84, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -31.68% YoY
Margins
- Gross margin
- 23.08%
- Operating margin
- 11.77%
- Net margin
- 10.88%
Key ratios & quality
- Altman Z-Scorei
- 6.84
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.36B | 1.35B | 1.35B | 1.78B | 3.15B | 2.33B | 4.26B | 2.91B |
| Gross profit | 222.86M | 179.59M | 160.66M | 337.06M | 1.20B | 541.57M | 1.85B | 672.05M |
| Selling & admin expenses | 177.05M | 178.24M | 183.94M | 198.63M | 232.21M | 252.63M | 314.45M | 329.29M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 45.81M | 1.35M | -23.28M | 138.43M | 964.25M | 288.95M | 1.54B | 342.76M |
| Pretax profit | 70.81M | 20.06M | -9.95M | 166.02M | 998.55M | 359.97M | 1.60B | 411.00M |
| Tax | 15.74M | 1.73M | -12.01M | 33.57M | 241.82M | 83.69M | 384.91M | 92.89M |
| Net profit | 55.06M | 18.33M | 2.06M | 132.44M | 756.73M | 276.28M | 1.22B | 318.11M |
| Basic EPS | 1 | 0 | 0 | 3 | 16 | 6 | 25 | 7 |
| Diluted EPS | 1.12 | 0.38 | 0.04 | 2.72 | 15.52 | 5.69 | 24.95 | 6.63 |
| Line item | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 | 2026-08 |
|---|---|---|---|---|---|---|
| Revenue | 1.10B | 922.60M | 769.50M | 666.95M | 552.58M | 539.61M |
| Gross profit | 531.51M | 311.31M | 207.39M | 119.28M | 34.07M | 403.00K |
| Selling & admin expenses | 94.92M | 69.51M | 82.89M | 83.30M | 93.59M | 81.65M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 436.59M | 249.29M | 124.50M | 35.98M | -59.52M | -81.25M |
| Pretax profit | 453.20M | 263.27M | 136.08M | 58.19M | -46.53M | -74.20M |
| Tax | 111.07M | 64.16M | 33.15M | 7.07M | -11.49M | -17.99M |
| Net profit | 342.13M | 199.11M | 102.93M | 51.12M | -35.04M | -56.20M |
| Basic EPS | 7 | 4 | 2 | 1 | -1 | -1 |
| Diluted EPS | 7.04 | 4.12 | 2.14 | 1.06 | -0.76 | -1.26 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 567.75M | 522.25M | 519.93M | 661.52M | 1.12B | 1.24B | 1.97B | 1.58B |
| Cash & ST investments | 319.43M | 232.29M | 169.51M | 174.51M | 647.91M | 812.38M | 1.39B | 924.06M |
| Inventory | 172.24M | 187.22M | 218.38M | 263.32M | 284.42M | 261.78M | 295.67M | 375.27M |
| Total assets | 1.16B | 1.21B | 1.23B | 1.43B | 1.95B | 2.18B | 3.08B | 3.11B |
| Total current liabilities | 74.91M | 93.18M | 90.10M | 184.67M | 182.73M | 227.74M | 308.37M | 205.52M |
| Short-term debt | 1.70M | 1.00M | 906.00K | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 166,472,000.00 | 197,019,000.00 | 216,393,000.00 | 323,144,000.00 | 344,942,000.00 | 387,718,000.00 | 518,604,000.00 | 467,038,000.00 |
| Total equity | 989.81M | 1.01B | 1.01B | 1.10B | 1.61B | 1.80B | 2.57B | 2.64B |
| Retained earnings | 954.53M | 975.15M | 975.98M | 1.07B | 1.57B | 1.76B | 2.57B | 2.77B |
| Line item | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 | 2026-08 |
|---|---|---|---|---|---|---|
| Total current assets | 1.97B | 1.85B | 1.75B | 1.75B | 1.58B | 1.47B |
| Cash & ST investments | 1.39B | 1.25B | 1.14B | 1.15B | 924.06M | 767.59M |
| Inventory | 295.67M | 328.43M | 340.59M | 348.91M | 375.27M | 394.69M |
| Total assets | 3.08B | 3.20B | 3.14B | 3.14B | 3.11B | 3.01B |
| Total current liabilities | 308.37M | 269.95M | 218.83M | 212.98M | 205.52M | 191.13M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 518,604,000.00 | 494,475,000.00 | 446,298,000.00 | 432,129,000.00 | 467,038,000.00 | 433,432,000.00 |
| Total equity | 2.57B | 2.70B | 2.70B | 2.71B | 2.64B | 2.58B |
| Retained earnings | 2.57B | 2.70B | 2.77B | 2.80B | 2.77B | 2.71B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 115.09M | 73.61M | 26.14M | 126.21M | 863.01M | 451.40M | 1.22B | 479.75M |
| Depreciation & amortization | 54.65M | 58.10M | 59.48M | 68.40M | 72.23M | 80.24M | 94.02M | 124.34M |
| Free cash flow | 47.10M | -50.57M | -68.93M | 53.81M | 726.44M | 304.28M | 1.06B | 328.53M |
| Dividends paid | -41.71M | 0 | -1.65M | -6.12M | -252.29M | -91.86M | -330.29M | -231.62M |
| Stock buybacks / issuance | -985.00K | -910.00K | -871.00K | -1.13M | -1.64M | -1.69M | -53.95M | -131.12M |
| Ending cash balance | 69.25M | 78.13M | 57.35M | 59.08M | 292.82M | 237.88M | 500.42M | 113.54M |
| Line item | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 | 2026-08 |
|---|---|---|---|---|---|---|
| Operating cash flow | 413.01M | 278.60M | 94.75M | 103.57M | 2.83M | -101.39M |
| Depreciation & amortization | 24.59M | 29.66M | 30.11M | 30.53M | 34.05M | 33.53M |
| Free cash flow | 367.15M | 233.30M | 47.92M | 71.99M | -24.68M | -153.00M |
| Dividends paid | -169.49M | -114.16M | -66.38M | -34.26M | -16.83M | 0 |
| Stock buybacks / issuance | -50.00M | -18.00K | -74.84M | -26.14M | -30.13M | -5.06M |
| Ending cash balance | 500.42M | 254.10M | 371.36M | 394.05M | 113.54M | 117.77M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 5.59 | 1.84 | 0.20 | 12.53 | 55.83 | 16.29 | 55.96 | 12.20 |
| ROA %i | 4.70 | 1.56 | 0.17 | 9.99 | 44.83 | 13.43 | 46.31 | 10.23 |
| ROIC %i | 4.98 | 1.43 | 0.01 | 12.46 | 54.82 | 14.86 | 54.28 | 10.82 |
| 5-year avg ROE %i | 15.01 | 10.41 | 2.64 | 6.84 | 15.20 | 17.34 | 28.16 | 30.56 |
| EBIT margin %i | 5.25 | 1.52 | -0.72 | 9.36 | 31.76 | 15.50 | 37.63 | 11.77 |
| FCF / sales %i | 3.46 | -- | -- | 3.03 | 23.09 | 13.08 | 24.95 | 11.28 |
| Current ratioi | 7.58 | 5.60 | 5.77 | 3.58 | 6.16 | 5.45 | 6.38 | 7.70 |
| Quick ratioi | 5.22 | 3.55 | 3.29 | 2.13 | 4.57 | 4.28 | 5.40 | 5.78 |
| Debt / assetsi | 0.22 | 0.28 | 0.19 | -- | -- | -- | -- | -- |
| LT debt / equityi | 0.09 | 0.24 | 0.15 | -- | -- | -- | -- | -- |
| Interest coveragei | 110.95 | 41.28 | -45.71 | 412.95 | 1,713.78 | 656.68 | 2,620.51 | -- |
| Revenue CAGR (3Y) %i | -10.66 | 7.95 | -3.54 | 9.30 | 32.53 | 19.92 | 33.85 | -2.55 |
| Net income CAGR (3Y) %i | -44.43 | -- | -74.62 | 34.74 | 245.43 | 412.86 | 109.52 | -25.24 |
| FCF CAGR (3Y) %i | -46.77 | -- | -- | 4.54 | -- | -- | 170.37 | -23.24 |
| Line item | 2025-05 | 2025-08 | 2025-11 | 2026-02 | 2026-05 | 2026-08 |
|---|---|---|---|---|---|---|
| ROE %i | 55.96 | 55.20 | 48.69 | 27.35 | 12.20 | 2.23 |
| ROA %i | 46.31 | 45.45 | 40.93 | 22.35 | 10.23 | 1.89 |
| ROIC %i | 54.28 | 53.49 | 46.95 | 25.76 | 10.82 | 0.89 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 37.63 | 37.92 | 35.93 | 26.17 | 11.77 | 0.48 |
| FCF / sales %i | 24.95 | 27.62 | 27.77 | 20.80 | 11.28 | -- |
| Current ratioi | 6.38 | 6.84 | 8.02 | 8.21 | 7.70 | 7.70 |
| Quick ratioi | 5.40 | 5.55 | 6.40 | 6.51 | 5.78 | 5.51 |
| Debt / assetsi | -- | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | 2,620.51 | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Diversified
- Specialty shell egg is the largest reported line at 43.91% of revenue, across 5 reported segments.
- No single line clears half of revenue; Conventional shell egg is next at 37.38%, spreading the business across more than one real driver.
Revenue breakdown most recent period
Business
Specialty shell egg43.91%
Conventional shell egg37.38%
Prepared foods11.67%
Other - segment sales10.31%
Quote time 2026-10-08 08:17:09 · For reference only, not investment advice and not tailored to your situation.